DUBLIN--(BUSINESS WIRE)--The "Gastrointestinal Therapeutics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global Gastrointestinal Therapeutics Market to Reach $84.4 Billion by 2027
The global market for Gastrointestinal Therapeutics estimated at US$61.2 Billion in the year 2020, is projected to reach a revised size of US$84.4 Billion by 2027, growing at a CAGR of 4.7% over the analysis period 2020-2027.
Crohn`s Disease, one of the segments analyzed in the report, is projected to record a 4.6% CAGR and reach US$16.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Ulcerative Colitis segment is readjusted to a revised 4.8% CAGR for the next 7-year period.
The U.S. Market is Estimated at $16.5 Billion, While China is Forecast to Grow at 7.5% CAGR
The Gastrointestinal Therapeutics market in the U.S. is estimated at US$16.5 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$17.5 Billion by the year 2027 trailing a CAGR of 7.5% over the analysis period 2020 to 2027.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 3.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$11.4 Billion by the year 2027.
GERD Segment to Record 5.1% CAGR
In the global GERD segment, USA, Canada, Japan, China and Europe will drive the 5.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$5.1 Billion in the year 2020 will reach a projected size of US$7.1 Billion by the close of the analysis period.
China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 5.5% CAGR through the analysis period.
What's New for 2022?
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and a Research Platform
- Complimentary updates for one year
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Gastrointestinal Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
- AbbVie, Inc.
- Alfa Wassermann, Inc.
- Allergan PLC
- Amgen, Inc.
- Anterogen Co., Ltd.
- Ardelyx, Inc.
- Astellas Pharma, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Biogen, Inc.
- Celgene Corporation
- Cosmo Pharmaceuticals NV
- Drais Pharmaceuticals, Inc.
- Eisai Co., Ltd.
- Eli Lilly and Company
- Enlivex Therapeutics ltd.
- F. Hoffmann-La Roche AG
- Ferring Pharmaceuticals, Inc.
- FF Pharma
- Galapagos NV
- Gilead Sciences, Inc.
- GlaxoSmithKline, Inc.
- Hutchison MediPharma Limited
- Immune Pharmaceuticals, Inc.
- InDex Pharmaceuticals Holding AB
- Ironwood Pharmaceuticals, Inc.
- Johnson & Johnson
- Kissei Pharmaceutical Co., Ltd.
- Kyowa Hakko Kirin Co., Ltd.
- Lexicon Pharmaceuticals, Inc.
- Lipid Therapeutics GmbH
- Meda AB
- Merck & Co., Inc.
- Mesoblast Ltd.
- Mitsubishi Tanabe Pharma Corporation
- Mochida Pharmaceutical Co., Ltd.
- Morphotek, Inc.
- Neovacs S.A.
- Nestle SA
- Norgine BV
- Novartis AG
- Pfizer, Inc.
- Procter & Gamble Company, The
- Qu Biologics Inc.
- RedHill Biopharma Ltd.
- Sterna Biologicals GmbH & Co. KG
- Synthetic Biologics, Inc.
- Takeda Pharmaceutical Co., Ltd.
- TiGenix NV
- Tillotts Pharma AG
- TopiVert Ltd.
- UCB SA
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. REGIONAL MARKET ANALYSIS
IV. COMPETITION
For more information about this report visit https://www.researchandmarkets.com/r/hhdnls
